GlassScriptPhysician profile
Bridget Margaret Blake
NPI 1649723107
$1,356.49
in general payments reported to CMS, 2019-2025
19 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.85 · 2022: $217 · 2023: $438 · 2024: $333 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Travel and Lodging: $17.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.85 |
| Travel and Lodging | $17.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $586.67 | 2022-2024 | Cardiomems, Mitraclip |
| Cvrx, INC. | $230.58 | 2024-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $74.99 | 2024-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $70.68 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.85 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $43.31 | 2024 | Evkeeza |
| Abiomed | $42.77 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.73 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $28.15 | 2023 | Arcalyst |
| Amgen INC. | $27.65 | 2023-2024 | Repatha |
| Irhythm Technologies, INC. | $27.26 | 2024 | Zio Xt Patch, Zio Monitor |
| Heartflow, INC. | $26.81 | 2024 | |
| Scpharmaceuticals INC. | $23.87 | 2024 | |
| Edwards Lifesciences Corporation | $23.23 | 2024 | Sapien 3 Ultra Resilia |
| Bridgebio Pharma, INC. | $16.32 | 2025 | Attruby |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $16.11 | 2024 | Opsumit |
| Pfizer INC. | $15.31 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.33 | 2024 | Farxiga |
| Daxor Corporation | $10.87 | 2024 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.